Avidity Partners Management’s Acceleron Pharma XLRN Stock Holding History

Avidity Partners Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-35,000	Closed	-$6.02M	–	120
2021 Q3	$6.02M	Sell	35,000 -323,500	-90%	-$42.3M	0.13%	80
2021 Q2	$45M	Buy	358,500 +35,700	+11%	+$4.5M	1.22%	30
2021 Q1	$43.8M	Buy	322,800 +23,800	+8%	+$3.07M	1.21%	29
2020 Q4	$38.3M	Buy	+299,000	New	+$35.1M	1.24%	28
2020 Q2	–	Sell	-166,000	Closed	-$14.9M	–	83
2020 Q1	$14.9M	Buy	+166,000	New	+$12.9M	2.06%	19

Avidity Partners Management's XLRN Position: Q4 2021 in Review

Avidity Partners Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 35,000 shares — an estimated $6.02M sold.

Avidity Partners Management first reported a position in XLRN in Q1 2020 and held it in 5 quarters. The position peaked at $45M in Q2 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Avidity Partners Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Avidity Partners Management sold 35,000 Acceleron Pharma shares in Q4 2021, an estimated $6.02M.
Avidity Partners Management first reported a position in Acceleron Pharma in Q1 2020 and held it in 5 quarters.
Avidity Partners Management's Acceleron Pharma position peaked at $45M in Q2 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Avidity Partners Management's 13F filing for Q4 2021, filed 14 Feb 2022.